🇺🇸 FDA
Patent

US 9701674

Substituted pyrazines as ATR kinase inhibitors

granted A61PA61P35/00

Quick answer

US patent 9701674 (Substituted pyrazines as ATR kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
61
CPC classes
A61P, A61P35/00